AU2005266739A1 - Carrier for medicaments for obtaining oral bioavailability - Google Patents

Carrier for medicaments for obtaining oral bioavailability Download PDF

Info

Publication number: AU2005266739A1
Authority: AU; Australia
Prior art keywords: protein; complex; protein complex; insulin; anyone
Prior art date: 2004-07-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2005266739A

Other languages

English (en)

Inventor

Jurgen Frevert

Thomas Stibora

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biotecon Therapeutics GmbH

Original Assignee

Biotecon Therapeutics GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-22

Filing date

2005-07-22

Publication date

2006-02-02

2005-07-22 Application filed by Biotecon Therapeutics GmbH filed Critical Biotecon Therapeutics GmbH

2006-02-02 Publication of AU2005266739A1 publication Critical patent/AU2005266739A1/en

Status Abandoned legal-status Critical Current

Links

239000003814 drug Substances 0.000 title description 5
108090000623 proteins and genes Proteins 0.000 claims description 129
102000004169 proteins and genes Human genes 0.000 claims description 125
108090000765 processed proteins & peptides Proteins 0.000 claims description 38
102000004196 processed proteins & peptides Human genes 0.000 claims description 37
229920001184 polypeptide Polymers 0.000 claims description 35
108030001720 Bontoxilysin Proteins 0.000 claims description 24
229940053031 botulinum toxin Drugs 0.000 claims description 22
241000193155 Clostridium botulinum Species 0.000 claims description 20
238000000034 method Methods 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 12
239000000872 buffer Substances 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
231100000252 nontoxic Toxicity 0.000 claims description 6
230000003000 nontoxic effect Effects 0.000 claims description 6
230000003067 hemagglutinative effect Effects 0.000 claims description 5
210000004898 n-terminal fragment Anatomy 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 4
239000003102 growth factor Substances 0.000 claims description 3
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
108090000695 Cytokines Proteins 0.000 claims description 2
102000004127 Cytokines Human genes 0.000 claims description 2
239000000427 antigen Substances 0.000 claims description 2
108091007433 antigens Proteins 0.000 claims description 2
102000036639 antigens Human genes 0.000 claims description 2
239000003114 blood coagulation factor Substances 0.000 claims description 2
108020001507 fusion proteins Proteins 0.000 claims description 2
102000037865 fusion proteins Human genes 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
239000000018 receptor agonist Substances 0.000 claims description 2
229940044601 receptor agonist Drugs 0.000 claims description 2
239000002464 receptor antagonist Substances 0.000 claims description 2
229940044551 receptor antagonist Drugs 0.000 claims description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 47
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
229940125396 insulin Drugs 0.000 description 24
102000004877 Insulin Human genes 0.000 description 22
108090001061 Insulin Proteins 0.000 description 22
241001465754 Metazoa Species 0.000 description 18
239000011780 sodium chloride Substances 0.000 description 17
239000000185 hemagglutinin Substances 0.000 description 16
239000003053 toxin Substances 0.000 description 13
231100000765 toxin Toxicity 0.000 description 13
108700012359 toxins Proteins 0.000 description 13
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
101710154606 Hemagglutinin Proteins 0.000 description 10
101710138657 Neurotoxin Proteins 0.000 description 10
101710093908 Outer capsid protein VP4 Proteins 0.000 description 10
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 10
101710176177 Protein A56 Proteins 0.000 description 10
238000000502 dialysis Methods 0.000 description 10
239000012634 fragment Substances 0.000 description 10
239000008103 glucose Substances 0.000 description 10
239000002581 neurotoxin Substances 0.000 description 10
231100000618 neurotoxin Toxicity 0.000 description 10
108010057266 Type A Botulinum Toxins Proteins 0.000 description 9
210000004900 c-terminal fragment Anatomy 0.000 description 9
230000000694 effects Effects 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
229940094657 botulinum toxin type a Drugs 0.000 description 7
239000000243 solution Substances 0.000 description 7
241001112696 Clostridia Species 0.000 description 5
108010085220 Multiprotein Complexes Proteins 0.000 description 5
102000007474 Multiprotein Complexes Human genes 0.000 description 5
241000700159 Rattus Species 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
238000007792 addition Methods 0.000 description 5
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
229910052921 ammonium sulfate Inorganic materials 0.000 description 5
239000001166 ammonium sulphate Substances 0.000 description 5
235000011130 ammonium sulphate Nutrition 0.000 description 5
238000013459 approach Methods 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
238000002955 isolation Methods 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
239000004365 Protease Substances 0.000 description 4
230000009471 action Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
241000894007 species Species 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000011109 contamination Methods 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
238000007446 glucose tolerance test Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
229930003779 Vitamin B12 Natural products 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
-1 antibodies Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000003304 gavage Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
229940090044 injection Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000010354 integration Effects 0.000 description 2
210000004347 intestinal mucosa Anatomy 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
210000001611 motor endplate Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000004739 secretory vesicle Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000007723 transport mechanism Effects 0.000 description 2
239000011715 vitamin B12 Substances 0.000 description 2
235000019163 vitamin B12 Nutrition 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
IXHADCPJRQNDGG-UHFFFAOYSA-N 3-[bis(2-chloroethyl)amino]-1-(4-phenylphenyl)propan-1-one Chemical compound C1=CC(C(=O)CCN(CCCl)CCCl)=CC=C1C1=CC=CC=C1 IXHADCPJRQNDGG-UHFFFAOYSA-N 0.000 description 1
UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 description 1
240000004507 Abelmoschus esculentus Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
101710117524 Botulinum neurotoxin type B Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000193163 Clostridioides difficile Species 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
101001012217 Conus geographus Con-Ins G3 Proteins 0.000 description 1
101001012221 Conus tulipa Con-Ins T3 Proteins 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
101710115215 Protease inhibitors Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102000000583 SNARE Proteins Human genes 0.000 description 1
108010041948 SNARE Proteins Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
238000010266 Sephadex chromatography Methods 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
102000002933 Thioredoxin Human genes 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000007819 coupling partner Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
229960005097 diphtheria vaccines Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229940093181 glucose injection Drugs 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
229940124736 hepatitis-B vaccine Drugs 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000004026 insulin derivative Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000026792 palmitoylation Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000013641 positive control Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
229940086526 renin-inhibitors Drugs 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960002766 tetanus vaccines Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
229950009811 ubenimex Drugs 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000012795 verification Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU2005266739A 2004-07-22 2005-07-22 Carrier for medicaments for obtaining oral bioavailability Abandoned AU2005266739A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102004035606.8		2004-07-22
DE102004035606A DE102004035606A1 (de)	2004-07-22	2004-07-22	Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
PCT/DE2005/001290 WO2006010360A2 (fr)	2004-07-22	2005-07-22	Vehicule permettant d'obtenir des medicaments a biodisponibilite orale

Publications (1)

Publication Number	Publication Date
AU2005266739A1 true AU2005266739A1 (en)	2006-02-02

Family

ID=35482323

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2005266739A Abandoned AU2005266739A1 (en)	2004-07-22	2005-07-22	Carrier for medicaments for obtaining oral bioavailability

Country Status (13)

Country	Link
EP (1)	EP1768701A2 (fr)
JP (1)	JP2008506724A (fr)
KR (1)	KR20070047786A (fr)
CN (1)	CN101340932A (fr)
AU (1)	AU2005266739A1 (fr)
BR (1)	BRPI0513715A (fr)
CA (1)	CA2574124A1 (fr)
DE (1)	DE102004035606A1 (fr)
IL (1)	IL180229A0 (fr)
MX (1)	MX2007000421A (fr)
NO (1)	NO20070775L (fr)
RU (1)	RU2006147284A (fr)
WO (1)	WO2006010360A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008169166A (ja) *	2007-01-14	2008-07-24	Tokyo Univ Of Agriculture & Technology	糖結合性ポリペプチド、複合材料、及び薬剤送達システム
JP2009132686A (ja) *	2007-10-26	2009-06-18	Okayama Univ	ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法
WO2009131435A1 (fr) *	2008-04-23	2009-10-29	Erasmus University Medical Center Rotterdam	Lieur contenant de la bungarotoxine et un peptide de liaison
WO2011075500A2 (fr) *	2009-12-18	2011-06-23	Allergan, Inc.	Stabilisation d'agents thérapeutiques pour faciliter l'administration
WO2013010782A2 (fr)	2011-07-15	2013-01-24	Nxp.B.V.	Commande d'un convertisseur résonant
EP3294754A4 (fr) *	2015-05-15	2019-04-03	Board of Regents of the University of Nebraska	Toxine de clostridium botulinum génétiquement modifiée, conçue pour acheminer des molécules jusque dans des cellules sélectionnées
CN115894719B (zh) *	2022-11-24	2023-10-20	武汉禾元生物科技股份有限公司	一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8914984D0 (en) *	1989-06-29	1989-08-23	Animal Health Inst	Nucleotide sequences
AU720857B2 (en) *	1995-12-13	2000-06-15	President And Fellows Of Harvard College	Use of toxin peptides and/or affinity handles for delivery compounds into cells
GB9617671D0 (en) *	1996-08-23	1996-10-02	Microbiological Res Authority	Recombinant toxin fragments
GB9824282D0 (en) *	1998-11-05	1998-12-30	Microbiological Research Agenc	Delivery of superoxide dismutase to neuronal cells
DE19856052A1 (de) *	1998-12-04	2000-06-08	Deutsches Krebsforsch	Konjugat zur Anreicherung in neuronalen Zellen
US6776990B2 (en) *	1999-04-08	2004-08-17	Allergan, Inc.	Methods and compositions for the treatment of pancreatitis
US6500436B2 (en) *	2000-01-19	2002-12-31	Allergan, Inc.	Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) *	2000-01-19	2003-11-04	Allergan, Inc.	Clostridial toxin derivatives and methods to treat pain
US6670322B2 (en) *	2000-06-01	2003-12-30	Wisconsin Alumni Research Foundation	Method of targeting pharmaceuticals to motor neurons
DE10035156A1 (de) *	2000-07-19	2002-02-07	Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh	Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20040220100A1 (en) *	2000-07-21	2004-11-04	Essentia Biosystems, Inc.	Multi-component biological transport systems
WO2003061694A1 (fr) *	2001-05-10	2003-07-31	Seattle Genetics, Inc.	Immunosuppression de la reponse immune humorale par des anticorps anti-cd20
GB0112687D0 (en) *	2001-05-24	2001-07-18	Microbiological Res Authority	Pharmaceutical use of secreted bacterial effector proteins
JP2005538954A (ja) *	2002-05-31	2005-12-22	トーマス・ジェファーソン・ユニバーシティ	分子の経上皮輸送用組成物及び方法
JP2007070225A (ja) *	2003-07-25	2007-03-22	Yukako Fujinaga	クロストリジウム属菌由来成分を含む医薬製剤
US20050129677A1 (en) *	2003-12-10	2005-06-16	Shengwen Li	Lipid rafts and clostridial toxins

2004
- 2004-07-22 DE DE102004035606A patent/DE102004035606A1/de not_active Withdrawn
2005
- 2005-07-22 KR KR1020077004107A patent/KR20070047786A/ko not_active Withdrawn
- 2005-07-22 AU AU2005266739A patent/AU2005266739A1/en not_active Abandoned
- 2005-07-22 RU RU2006147284/15A patent/RU2006147284A/ru not_active Application Discontinuation
- 2005-07-22 BR BRPI0513715-2A patent/BRPI0513715A/pt not_active IP Right Cessation
- 2005-07-22 WO PCT/DE2005/001290 patent/WO2006010360A2/fr active Application Filing
- 2005-07-22 CA CA002574124A patent/CA2574124A1/fr not_active Abandoned
- 2005-07-22 MX MX2007000421A patent/MX2007000421A/es not_active Application Discontinuation
- 2005-07-22 JP JP2007521791A patent/JP2008506724A/ja active Pending
- 2005-07-22 EP EP05771235A patent/EP1768701A2/fr not_active Withdrawn
- 2005-07-22 CN CNA2005800244861A patent/CN101340932A/zh active Pending
2006
- 2006-12-21 IL IL180229A patent/IL180229A0/en unknown
2007
- 2007-02-09 NO NO20070775A patent/NO20070775L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE102004035606A1 (de)	2006-03-30
BRPI0513715A (pt)	2008-05-13
EP1768701A2 (fr)	2007-04-04
RU2006147284A (ru)	2008-08-27
WO2006010360A3 (fr)	2007-12-27
JP2008506724A (ja)	2008-03-06
MX2007000421A (es)	2007-03-28
WO2006010360A2 (fr)	2006-02-02
IL180229A0 (en)	2007-07-04
CN101340932A (zh)	2009-01-07
KR20070047786A (ko)	2007-05-07
CA2574124A1 (fr)	2006-02-02
NO20070775L (no)	2007-04-18

Legal Events

Date	Code	Title	Description
2009-06-25	MK1	Application lapsed section 142(2)(a) - no request for examination in relevant period
2009-06-25	NB	Applications allowed - extensions of time section 223(2)	Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 14 JUN 2009.
2011-02-17	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application

Publication	Publication Date	Title
EP1235594B1 (fr)	2012-06-13	Inhibition de la secretion de cellules non neuronales
US20060216283A1 (en)	2006-09-28	Inhibition of secretion from non-neuronal cells
RU2412253C2 (ru)	2011-02-20	Рекомбинантная экспрессия белков в двухцепочечной форме с дисульфидным мостиком
US8852603B2 (en)	2014-10-07	Inhibition of secretion from non-neuronal cells
AU2001285688B2 (en)	2005-09-08	Protein complex serving as a vehicle for orally administerable medicaments
JP2001522783A (ja)	2001-11-20	経口ワクチンおよび治療剤を全身にデリバリーするための組成物および方法
TWI642444B (zh)	2018-12-01	糖鏈加成連接基、含有糖鏈加成連接基與生理活性物質的化合物或其鹽，以及其製造方法
EP1523336B1 (fr)	2008-08-20	Agents cibles de regeneration des nerfs
AU2005266739A1 (en)	2006-02-02	Carrier for medicaments for obtaining oral bioavailability
BR112012019992A2 (pt)	2020-08-18	conjugados de igf-i poli (etileno glicol)
CN102949731A (zh)	2013-03-06	与glp-2受体特异性结合的药物融合体
AU2008241572B2 (en)	2011-01-27	Inhibition of secretion from non-neuronal cells
Reidy	2007	Engineering of the RTB lectin as a carrier platform for proteins and antigens
CN103509119A (zh)	2014-01-15	一种短肽激素与重组假单胞菌外毒素a的重组融合蛋白及应用
WO2007118889A1 (fr)	2007-10-25	Protéase spécifique pour l'inactivation du facteur de nécrose tumorale alpha humain